CN103191235A - Traditional Chinese medicine compound extract for preventing and treating hyperuricemia and application - Google Patents
Traditional Chinese medicine compound extract for preventing and treating hyperuricemia and application Download PDFInfo
- Publication number
- CN103191235A CN103191235A CN2013101068613A CN201310106861A CN103191235A CN 103191235 A CN103191235 A CN 103191235A CN 2013101068613 A CN2013101068613 A CN 2013101068613A CN 201310106861 A CN201310106861 A CN 201310106861A CN 103191235 A CN103191235 A CN 103191235A
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- medicine compound
- compound extract
- extract
- traditional chinese
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a traditional Chinese medicine compound extract for preventing and treating hyperuricemia. The traditional Chinese medicine compound extract is prepared from three crude medicines namely root of kudzu vine, pericarpium citri reticulatae and pine needle in the processes of mixing and crushing the crude medicines according to the mass ratio of (30-70) to (20-60) to (20-60), refluxing and extracting by ethanol, and concentrating and drying the filtrate by reduced pressure. By adopting the traditional Chinese medicine compound extract, the UA (uric acid)) level of rat serum of hyperuricemia can be reduced; the xanthine oxidase (XOD) activities of the serum and the liver are reduced; and the aadenosine deaminase deficiency (ADA) activities of the liver and the serum are also reduced.
Description
Technical field
The present invention relates to the antihyperuricemic disease drug, be specifically related to a kind of Chinese medicine compound extract and application for prevention and treatment hyperuricemia.
Background technology
Hyperuricemia be one group with heritability and/or acquired cause that urate excretion reduces and/or body in the purine metabolism obstacle, thereby a kind of disease that causes blood uric acid to increase.Continue development and can cause diseases such as gout acute attack, urate nephropathy, and relevant with hypertension, hyperlipidemia, obesity, insulin resistant, diabetes etc., be a kind of serious metabolic disease of harm humans health.Existing uric acid resisting Western medicine mainly is: 1. suppress the uricopoiesis medicine, as allopurinol; 2. promote the urate excretion medicine, as probenecid, sulfinpyrazone, benzbromarone etc.Chinese prescription is also varied, be the application for a patent for invention of CN 102188634 as publication number, disclosing by Flos Sophorae, Flos Lonicerae or Flos Lonicerae, Rhizoma Alismatis, Rhizoma Phragmitis and Rhizoma Imperatae is the pharmaceutical composition that raw material is prepared from by the certain part by weight proportioning, publication number is the patent of invention of CN1846753, and then disclosing with Radix Astragali extract, Cortex Fraxini extract and Folium Camelliae sinensis extract is the pharmaceutical composition of major ingredient.
Summary of the invention
Technical problem to be solved by this invention provides a kind of Chinese medicine compound extract for prevention and treatment hyperuricemia, this Chinese medicine compound extract can reduce the UA level of the rat blood serum of hyperuricemia, reduce the XOD activity of serum regulating liver-QI, reduce the ADA activity of the liver of serum.
The present invention solves the problems of the technologies described above the technical scheme that adopts: a kind of Chinese medicine compound extract for prevention and treatment hyperuricemia, by weight 30～70:20～60:20～60, Radix Puerariae, Pericarpium Citri Reticulatae and three kinds of medical materials of Folium Pini are mixed the back to be pulverized, through alcohol reflux, filtrate decompression concentrate and drying after the Chinese medicine compound extract that obtains.
Concrete extracting mode: press component above-mentioned three flavor medical materials are mixed the back pulverizing, 5～20 times of weight concentrations that add the medical material gross weight are 10～70% alcohol reflux 2～4 times, each 0.5～3.0 h, filter, filtrate decompression concentrates, 55～65 ℃ of thickening temperatures, and it is 1.00～1.20 that filtrate decompression is concentrated into relative density, dry again, obtain the Chinese medicine compound extract.
This Chinese medicine compound extract is used in the medicine for preparing prevention and treatment hyperuricemia or food; This Chinese medicine compound extract of medicament preparation can be formed tablet, capsule, pill, granule or oral liquid etc. with the guidance material of pharmaceutically approval.This Chinese medicine compound extract of food preparation can low dose of be added in the health food of various permission additions.
Compared with prior art, the invention has the advantages that a kind of Chinese medicine compound extract for prevention and treatment hyperuricemia, by weight than 30～70:20～60:20～60, Radix Puerariae, Pericarpium Citri Reticulatae and three kinds of medical materials of Folium Pini are mixed the back to be pulverized, through alcohol reflux, filtrate decompression concentrate and drying after the Chinese medicine compound extract that obtains; This Chinese medicine compound extract can reduce the UA level of the rat blood serum of hyperuricemia, reduces the XOD activity of serum regulating liver-QI, reduces the ADA activity of the liver of serum.
The specific embodiment
Describe in further detail below in conjunction with the present invention of embodiment.
Embodiment 1
Take by weighing 40 kilograms of 50 kilograms of Radix Puerariaes, 40 kilograms of Pericarpium Citri Reticulataes and Folium Pinis, three kinds of medical materials mix the back and pulverize, 12 times of weight concentrations that add the medical material gross weight are 40% alcohol reflux 3 times, each 0.5～3.0 h filters, and filtrate decompression concentrates, 55～65 ℃ of thickening temperatures, it is 1.00～1.20 that filtrate decompression is concentrated into relative density, dry again, obtains the Chinese medicine compound extract.
Embodiment 2
Take by weighing 20 kilograms of 70 kilograms of Radix Puerariaes, 20 kilograms of Pericarpium Citri Reticulataes and Folium Pinis, three kinds of medical materials mix, and 5 times of weight concentrations that add the medical material gross weight are 70% alcohol reflux 2 times.
Embodiment 3
Take by weighing 60 kilograms of 30 kilograms of Radix Puerariaes, 30 kilograms of Pericarpium Citri Reticulataes and Folium Pinis, three kinds of medical materials mix, and 20 times of weight concentrations that add the medical material gross weight are 10% alcohol reflux 4 times.
Embodiment 4
Take by weighing 20 kilograms of 40 kilograms of Radix Puerariaes, 60 kilograms of Pericarpium Citri Reticulataes and Folium Pinis, three kinds of medical materials mix, and 16 times of weight concentrations that add the medical material gross weight are 20% alcohol reflux 4 times.
The said extracted thing can be made tablet, capsule, pill, granule or oral liquid with the various pharmaceutically adjuvants of approval, oral taking, and every day, consumption was at 1.5～15g extract/kg rat body weight.
Toxicological test
120 of SD rats carry out 6 months long term toxicity tests.Each group gives 100 times, 50 times and 25 times of the clinical plan consumption of extract of the present invention respectively) and blank.Every day, gastric infusion was 1 time, successive administration 182 days.Divide interim the inspection three times, i.e. administration mid-term (administration 3 months), drug withdrawal next day (administration 6 months) and convalescent period finish (4 weeks of drug withdrawal) inspection.Through overview, food ration, body weight weighing, hematology and biochemical analysis, see and histopathological examination substantially.It is safe that the result is presented at the interior administration of suitable amount ranges, does not have obvious retardance toxicity.The acute toxicity tests shows that 48 of ICR mices were observed 14 days continuously, and the extract of the present invention that is equivalent to 250 times of clinical plan consumptions is irritated stomach, does not also have lethal dose.
Pharmacodynamics test
Animal grouping: SD rat, male, be divided at random: the normal control group, model control group, embodiment 1 dosage group: extract 7.5g/kg dosage, embodiment 1 dosage group: extract 5.0 g/kg, embodiment 1 dosage group: extract 2.5g/kg, embodiment 2 dosage groups: extract 15g/kg, embodiment 2 dosage groups: extract 7.0g/kg, embodiment 2 dosage groups: extract 3.5g/kg, embodiment 3 dosage groups: extract 5.5g/kg, embodiment 3 dosage groups: extract 3.0g/kg, embodiment 3 dosage groups: extract 1.5g/kg, allopurinol group 0.015g/kg, 10 ~ 12 every group.
Pathological model: except the normal control group, all the other each groups give the high purine feedstuff of 10% yeast extract and 0.1% adenine, and continuous 21 days, preparation hyperuricemia pathological model.
Administering mode: each treated animal is irritated stomach once every day, irritates the stomach volume and is the 1ml/100g body weight, continuous 21 days; Normal control group and model control group give the water of respective volume, and other group gives medicinal liquid.
Index determining: fasting 12h after the last administration, postcava is got blood, and separation of serum is measured uric acid (UA), xanthine oxidase (XOD) and ADA Adenosine deaminase (ADA) activity in the serum.
Table 1: to hyperuricemia rat animal UA level, XOD activity, ADA activity influence (
P＜0.05)
| Group | Serum UA/ μ molL -1 | Serum XOD/UL -1 | Liver XOD/Ugprot -1 | Serum ADA/Uml -1 | Liver ADA/Umgprot -1 |
| Normal group | 70.23±23.75 | 26.12±7.82 | 15.07±6.50 | 15.78±5.92 | 7.23±2.95 |
| Model group | 150.35±50.24 | 38.75±10.23 | 23.27±8.19 | 25.25±6.34 | 14.32±5.27 |
| 7.5g/ group | 76.53±22.34 | 28.75±4.76 | 15.33±4.78 | 16.57±3.38 | 7.95±2.14 |
| 5.0g/ group | 91.24±29.35 | 30.92±5.25 | 18.21±4.71 | 18.55±4.58 | 9.88±3.15 |
| 2.5g/ group | 72.66±13.28 | 27.32±5.50 | 17.57±5.38 | 18.30±3.92 | 10.31±2.93 |
| The 15g/ group | 87.05±19.98 | 30.02±4.73 | 19.20±2.83 | 17.14±1.42 | 10.48±1.60 |
| 7.0g/ group | 93.46±23.16 | 28.62±3.23 | 17.83±3.56 | 18.07±3.01 | 8.50±1.52 |
| 3.5g/ group | 100.48±17.08 | 32.35±2.10 | 18.27±4.62 | 17.26±2.04 | 9.42±1.45 |
| 5.5g/ group | 82.87±13.99 | 31.42±3.76 | 16.44±4.12 | 18.39±2.68 | 9.10±1.66 |
| 3.0g/ group | 79.90±19.35 | 29.12±3.24 | 15.94±3.43 | 17.17±2.92 | 9.06±1.92 |
| 1.5g/ group | 108.63±14.01 | 33.34±3.03 | 19.74±1.43 | 19.37±2.60 | 11.13±2.18 |
| Allopurinol | 84.81±25.27 | 28.25±3.77 | 15.52±4.96 | 16.71±3.05 | 9.28±4.73 |
Each dosage of herbal mixture extract of the present invention all can reduce hyperuricemia rat blood serum UA level to some extent as can be seen from Table 1, reduces serum and liver XOD activity, reduces serum and liver ADA activity.
Claims (2)
1. Chinese medicine compound extract that is used for prevention and treatment hyperuricemia, it is characterized in that by weight 30～70:20～60:20～60, Radix Puerariae, Pericarpium Citri Reticulatae and three kinds of medical materials of Folium Pini are mixed the back to be pulverized, through alcohol reflux, filtrate decompression concentrate and drying after the Chinese medicine compound extract that obtains.
2. a kind of Chinese medicine compound extract for prevention and treatment hyperuricemia as claimed in claim 1 is characterized in that by weight 50:40:40, Radix Puerariae, Pericarpium Citri Reticulatae and three kinds of medical materials of Folium Pini is mixed the back pulverize.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310106861.3A CN103191235B (en) | 2013-03-29 | 2013-03-29 | Traditional Chinese medicine compound extract for preventing and treating hyperuricemia and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310106861.3A CN103191235B (en) | 2013-03-29 | 2013-03-29 | Traditional Chinese medicine compound extract for preventing and treating hyperuricemia and application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103191235A true CN103191235A (en) | 2013-07-10 |
| CN103191235B CN103191235B (en) | 2014-08-13 |
Family
ID=48714169
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310106861.3A Active CN103191235B (en) | 2013-03-29 | 2013-03-29 | Traditional Chinese medicine compound extract for preventing and treating hyperuricemia and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103191235B (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109512878A (en) * | 2018-12-20 | 2019-03-26 | 宁波泰康红豆杉生物工程有限公司 | The method that thick grass acid content improves in loose Pueraria lobota anti-trioxypurine particle preparation |
| CN109512879A (en) * | 2018-12-20 | 2019-03-26 | 宁波泰康红豆杉生物工程有限公司 | The method that isoflavone content improves in loose Pueraria lobota anti-trioxypurine particle preparation |
| CN109602802A (en) * | 2018-12-20 | 2019-04-12 | 浙江大学宁波理工学院 | The method that flavones content improves in loose Pueraria lobota anti-trioxypurine particle preparation |
| CN109602803A (en) * | 2018-12-20 | 2019-04-12 | 浙江大学宁波理工学院 | The method that limonin content improves in loose Pueraria lobota anti-trioxypurine particle preparation |
| CN111184796A (en) * | 2018-11-15 | 2020-05-22 | 山东理工大学 | Preparation method of black nightshade extract for reducing hyperuricemia uric acid |
| CN112043599A (en) * | 2020-09-02 | 2020-12-08 | 广东微纳生物科技有限公司 | Method for preparing uric acid-reducing powder by nanotechnology and processing equipment |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101002848A (en) * | 2007-01-29 | 2007-07-25 | 张光辉 | Medicine for treating recurrent uarthritis, and its preparing method |
| CN101126057A (en) * | 2007-08-09 | 2008-02-20 | 王涛 | Kudzu root health care medicinal liquor |
| CN102526263A (en) * | 2011-12-20 | 2012-07-04 | 瑞坝（北京）新能源科技有限公司 | Plant health care product for preventing and treating gout |
-
2013
- 2013-03-29 CN CN201310106861.3A patent/CN103191235B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101002848A (en) * | 2007-01-29 | 2007-07-25 | 张光辉 | Medicine for treating recurrent uarthritis, and its preparing method |
| CN101126057A (en) * | 2007-08-09 | 2008-02-20 | 王涛 | Kudzu root health care medicinal liquor |
| CN102526263A (en) * | 2011-12-20 | 2012-07-04 | 瑞坝（北京）新能源科技有限公司 | Plant health care product for preventing and treating gout |
Non-Patent Citations (1)
| Title |
|---|
| 芳姐: "《www.healthy-food.hk/?p=3743》", 14 December 2012 * |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111184796A (en) * | 2018-11-15 | 2020-05-22 | 山东理工大学 | Preparation method of black nightshade extract for reducing hyperuricemia uric acid |
| CN109512878A (en) * | 2018-12-20 | 2019-03-26 | 宁波泰康红豆杉生物工程有限公司 | The method that thick grass acid content improves in loose Pueraria lobota anti-trioxypurine particle preparation |
| CN109512879A (en) * | 2018-12-20 | 2019-03-26 | 宁波泰康红豆杉生物工程有限公司 | The method that isoflavone content improves in loose Pueraria lobota anti-trioxypurine particle preparation |
| CN109602802A (en) * | 2018-12-20 | 2019-04-12 | 浙江大学宁波理工学院 | The method that flavones content improves in loose Pueraria lobota anti-trioxypurine particle preparation |
| CN109602803A (en) * | 2018-12-20 | 2019-04-12 | 浙江大学宁波理工学院 | The method that limonin content improves in loose Pueraria lobota anti-trioxypurine particle preparation |
| CN112043599A (en) * | 2020-09-02 | 2020-12-08 | 广东微纳生物科技有限公司 | Method for preparing uric acid-reducing powder by nanotechnology and processing equipment |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103191235B (en) | 2014-08-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103191235B (en) | Traditional Chinese medicine compound extract for preventing and treating hyperuricemia and application | |
| CN101450095A (en) | Medicine composition with blood-sugar reduction function and preparation method thereof | |
| CN101732517B (en) | Chinese medicinal composition for treating canine distemper and preparation method thereof | |
| CN104138469A (en) | Medicinal composite preparation for treating type 2 diabetes and reversing insulin resistance, and preparation method thereof | |
| CN101474375A (en) | Compound Cordyceps militaris L. Link preparation and production method and application | |
| CN101450101A (en) | Medicine composition with blood-sugar reduction function and preparation method thereof | |
| CN101433667A (en) | Pharmaceutical composition with function for reducing blood sugar and preparation method thereof | |
| CN115414458B (en) | A Chinese medicinal composition for treating hepatitis B, and its preparation method | |
| CN107319332A (en) | A kind of integration of drinking and medicinal herbs composition with hypoglycemic effect and preparation method thereof | |
| CN104069194B (en) | A kind of Chinese medicine composition with antitumaous effect and its production and use | |
| CN103705578B (en) | There is blood fat reducing and Chinese medicine preparation suppressing blood glucose rising effect and preparation method thereof | |
| CN1709299A (en) | Chinese medicine formulation for treating asthma and its preparing method | |
| CN106038702B (en) | Antifatigue composition and its preparation method and application | |
| CN101491605A (en) | Combination with blood sugar reducing function and preparation method thereof | |
| CN112022966B (en) | Traditional Chinese medicine composition for preventing, relieving and/or treating hyperuricemia | |
| CN101606964B (en) | Veterinary traditional Chinese medical compound preparation | |
| CN105327115A (en) | Phellinus linteus catharsis formula for prevention and cure of type II diabetes and preparation process thereof | |
| CN100464767C (en) | Medicine composition for treating hyperuricemia | |
| CN101816708B (en) | Chinese medicinal composition for curing rheumatism and preparation method thereof | |
| CN101450162A (en) | Traditional Chinese medicine composition with blood-sugar reduction function and preparation method thereof | |
| CN101450174A (en) | Medicine composition with blood-sugar reduction function and preparation method thereof | |
| CN108704036A (en) | A kind of Chinese traditional compound medicine and preparation method thereof for treating gout | |
| CN115554345B (en) | A Chinese medicinal compound preparation for treating gout and hyperuricemia, and its preparation method | |
| CN103432204B (en) | Traditional Chinese medicine effective part composition for treating schizophrenia and preparation method thereof | |
| CN102688254B (en) | Medicinal composition for treating chronic diarrhea and preparation method and use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |